Newsroom | 11151 results

AUSTIN, Texas--(BUSINESS WIRE)--Revival Healthcare Capital Announces Strategic Partnership with Olympus to Jointly Invest up to $458 Million into Swan EndoSurgical....

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Ca...

PENANG, Malaysia--(BUSINESS WIRE)--Straits Orthopaedics (Mfg) Sdn Bhd (“Straits”), a leading Malaysia-based contract manufacturer specializing in the precision machining of orthopaedic implants and surgical instruments, today announced the successful acquisition of Medin Technologies, Inc. (“Medin”), a U.S.-based manufacturer of sterilization cases and trays for the orthopaedic sector operating two facilities in Totowa, New Jersey, and Manchester, New Hampshire. This strategic acquisition repre...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomati...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy has received FDA approval to streamline the stool collection process for ColoSense®, its RNA-based colorectal cancer screening test....

PITTSBURGH--(BUSINESS WIRE)--Plexision, a biotechnology company, today announced a $365,000 investment from the Richard King Mellon Foundation. The funds will be used to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities across Plexision’s suite of cell-based blood tests, significantly improving predictive accuracy for complex transplant outcomes. Despite advances in transplant medicine, managing immunosuppressive drugs remains a delicate balance....

LEBANON, N.H.--(BUSINESS WIRE)--Cairn Surgical, an innovative medical device firm striving to make breast cancer surgery more precise, achieves ISO 13485 certification....

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ability of Prospera in assessing outcomes following kidney transplant rejection. PEDAL enrolled 488 kidney transplant re...

ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis debuts SurgiBind® Tendon Protect, a fish-skin graft for tendon repair, at APMA 2025; now available across the U.S....

HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a biotechnology company pioneering autologous regenerative cell therapies, today announced the publication of a pivotal preclinical study in the International Journal of Molecular Sciences, further validating the regenerative mechanism of its proprietary cell therapy platform for tendon repair. The study, titled "Regeneration of Biomechanically Functional Tendon Tissue Following Injection of Uncultured, Autologous, Adipose-Derived Regenerative Cells [U...